Patent suit against Osteometer (Denmark) withdrawn:
This article was originally published in Clinica
Executive Summary
Ostex International (US) has withdrawn legal action against Osteometer (Denmark) in the Netherlands in which it alleged patent infringement of technology incorporated in the bone resorption assay, Osteomark (see Clinica No 663, p 15). Osteometer is working with Cortecs on the development of a doctor's office test for osteoporosis using Osteometer's CrossLaps technology which was the subject of the legal action. Cortecs aims to launch the test this calendar year, says president Dr Michael Flynn.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.